FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE** COMMISSION

Washington, D.C. 20549

	OMB APPROVAL										
1	OMB Number:	3235-0287									
	Estimated average burden										
	hours per response:	0.5									

	Check this box if no longer subject
$\overline{}$	to Section 16. Form 4 or Form 5
$\cup$	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name at Blackn (Last) 2000 SIF (Street) BRISBA (City)	2. Issuer Name and Ticker or Trading Symbol  Day One Biopharmaceuticals, Inc. [ DAWN ]  3. Date of Earliest Transaction (Month/Day/Year)  06/05/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)  Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See																	
Table I - Non-Derivat  1. Title of Security (Instr. 3)  2. Transactic Date (Month/Day/						on 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr. and 5)		uired (A) o	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock 06/05/20						023			S <sup>(1)</sup>		1,229	D	\$10	5 1,23	1,234,363		D	
Common Stock														1,00	1,000,000		I	By the 2021 Blackman Family LLC <sup>(2)</sup>
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ive Conversion or Exercise Price of Derivative Security    Date (Month/Day/Year)   Execution Date, if any (Month/Day/Year)			ransaction of Operivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)	rivative derivativ curity Securitie		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2022.
- 2. The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.

## Remarks:

/s/ Charles N. York II, as Attorney-in-Fact

06/07/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.